Provocative Information About Rapamycin

Results:? The mean IOP at T1 was 15.3?��?7.5?mmHg http://www.selleck.cn/products/Bleomycin-sulfate.html in group A and 47.1?��?24.1?mmHg in group B (difference ?31.85?mmHg, 95% Confidence interval ?40.13 to ?23.56; p? http://www.selleckchem.com/products/MG132.html (Avery et?al. 2006; VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group 2006: p. 1508�C1521; Rosenfeld et?al. 2006). VEGF-inhibitors must be administered through intravitreous injections every 4�C6?weeks depending on the product used. Anti-VEGF injections have been reported to have a transient effect on intraocular pressure (IOP) mainly because of an acute volume-related IOP elevation that will occur after any intraocular injection (Kotliar et?al. 2007). Acute IOP elevation has been reported to potentially increase the risk of intraocular circulatory disorders http://www.selleckchem.com/products/Rapamycin.html (Chew et?al. 1987; Coden et?al. 1988; Yan et?al. 1994; Michelson et?al. 1996; Schulte et?al. 1996; Riva et?al. 1997). The use of anterior chamber paracentesis in combination with intravitreal anti-VEGF injections is inconsistent, and there is no consensus regarding its necessity (Aiello et?al. 2004; Jager et?al. 2004). According to earlier publications on pegaptanib injections and their effect on IOP, anterior chamber paracentesis has not been used as part of the routine procedure (Hariprasad et?al. 2006; Bakri et?al. 2007; Frenkel et?al. 2007). The aim of this prospective randomized study was to investigate whether prophylactic anterior chamber paracentesis affects the immediate postoperative IOP after pegaptanib injections. In addition, the possible sensation of discomfort or pain experienced by the patients during the injection procedure is assessed. The study cohort included 41 eyes of 41 patients with exudative AMD receiving treatment at the Department of Ophthalmology, Central Hospital of Lahti, from January 2007 to October 2007. Each patient received between one and three pegaptanib (Macugen?; Pfizer Ltd, UK) injections adding up to 73 pegaptanib injections. Each patient was randomly assigned either into one of two study groups: in group A (20 patients, n?=?35 injections) prophylactic anterior chamber paracentesis was performed prior to the injection and in group B (21 patients, n?=?38 injections) no paracentesis was performed.